GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GlycoMimetics Inc.
Canoo is an electric vehicle startup with a unique modular design. Its stock price is a story of struggle for survival. The chart reflects the constant need for funding, production delays, and intense competition in the EV market.
Share prices of companies in the market segment - Oncology targeted therapy
GlycoMimetics is a biopharmaceutical company developing drugs that mimic the functions of carbohydrates for the treatment of cancer and inflammatory diseases. We have classified it in the "Targeted Oncology" segment. The chart below shows how the market evaluates innovative approaches in biotechnology.
Broad Market Index - GURU.Markets
GlycoMimetics is a biotech company developing drugs that mimic the structure of carbohydrates to treat cancer and inflammatory diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how GlycoMimetics shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GLYC - Daily change in the company's share price GlycoMimetics Inc.
For GlycoMimetics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
GlycoMimetics is a biopharmaceutical company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. Oncology is a volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating GLYC stock.
Daily change in the price of a broad market stock, index - GURU.Markets
GlycoMimetics is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GlycoMimetics Inc.
GlycoMimetics, Inc.'s year-over-year performance is a story about its development of drugs for the treatment of blood diseases. Its 12-month market cap is entirely dependent on clinical trial data. The failure of its lead drug for acute myeloid leukemia was a serious blow, and its valuation now hinges on its faith in its other developments.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
GlycoMimetics, a late-stage biotech company, is developing drugs to treat blood cancer. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GlycoMimetics is a biotech company whose value is locked into its cancer drug pipeline. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GlycoMimetics Inc.
GlycoMimetics is a late-stage oncology company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its blood cancer drug is the key event shaping expectations.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
GlycoMimetics is a biotech company developing drugs that target carbohydrate molecules on the cell surface. This is an innovative approach to treating cancer and inflammatory diseases. The dynamics of the biotech sector, as shown in the graph, reflect the overall context in which GlycoMimetics is trying to prove that its unique scientific platform can deliver results.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
GlycoMimetics, Inc. is a clinical-stage biopharmaceutical company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. The company's future depends on the success of its clinical trials. The broader market chart serves as just a backdrop to understand how its unique scientific approach has impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotech company focused on the treatment of blood cancers and inflammatory diseases. Its weekly stock price is highly volatile and depends on news of clinical trial results.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
GlycoMimetics develops drugs that target carbohydrate molecules to treat cancer and inflammatory diseases. This is a new approach in pharmaceuticals. The chart will show whether GlycoMimetics' share price fluctuations are driven by its unique clinical data or reflect the overall sentiment of investors in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GlycoMimetics is a clinical-stage biotech company. Its shares are buoyed by anticipation of trial results. The chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
GLYC - Market capitalization of the company GlycoMimetics Inc.
GlycoMimetics' market capitalization dynamics are a volatile chart for a biotech company focused on treating cancer and inflammatory diseases. Its market valuation depends entirely on the results of clinical trials. Sharp movements on the chart reflect investors' reactions to any data that could bring its drugs closer or further away from market launch.
GLYC - Share of the company's market capitalization GlycoMimetics Inc. within the market segment - Oncology targeted therapy
GlycoMimetics is a biotech company focused on developing drugs to treat cancer and inflammatory diseases. Its market share in the pharmaceutical sector is very small, as is typical for a research firm. Its market capitalization is entirely dependent on clinical trial news, reflecting the high risks and expectations of investors.
Market capitalization of the market segment - Oncology targeted therapy
Here's a chart showing the biotech sector's market capitalization. GlycoMimetics is a company developing a new generation of drugs targeting carbohydrate molecules that play a key role in the development of cancer and inflammation. Its market history exemplifies how a unique scientific approach can open up entirely new avenues for treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
GlycoMimetics is a biotech company developing drugs that target carbohydrate molecules that play a key role in cancer and inflammation. Its market capitalization is a bet on this scientific approach. The chart below shows the economic weight of the glycobiology sector.
Book value capitalization of the company, segment and market as a whole
GLYC - Book value capitalization of the company GlycoMimetics Inc.
GlycoMimetics' foundation is its intellectual property in a portfolio of drugs targeting carbohydrate molecules for the treatment of cancer and inflammatory diseases. The chart tells the story of a biotech company that, after clinical trial failures, uses its remaining capital to advance earlier candidates in its pipeline.
GLYC - Share of the company's book capitalization GlycoMimetics Inc. within the market segment - Oncology targeted therapy
GlycoMimetics develops drugs that target carbohydrate molecules. The chart shows its share of actual R&D assets. These are its laboratories, where new approaches to treating cancer and inflammatory diseases are being researched, and these constitute its scientific resources.
Market segment balance sheet capitalization - Oncology targeted therapy
GlycoMimetics is a biotech company specializing in drugs that target carbohydrate molecules. Their primary assets are patents and scientific data. The book value chart shows their R&D base, which is just the tip of the iceberg of their scientific potential.
Book value of all companies included in the broad market index - GURU.Markets
GlycoMimetics' resources include laboratories and R&D centers for developing drugs targeting carbohydrate biology for the treatment of cancer and inflammation. The chart shows how the company built its scientific and physical capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GlycoMimetics Inc.
GlycoMimetics is a biotech company focused on treating cancer and inflammatory diseases. Its assets are intellectual property. The chart below is a pure barometer of hope. Its movements will reflect not changes in assets, but news about clinical trials, which determine the company's future.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
GlycoMimetics is a clinical-stage biotechnology company developing drugs for the treatment of diseases based on carbohydrate interactions. Its valuation is entirely dependent on clinical trial results. The schedule reflects the high risk and potential of its unique scientific approach.
Market to book capitalization ratio for the market as a whole
GlycoMimetics is a biotech company developing cancer drugs. Its market value is almost entirely dependent on clinical trial results. This chart demonstrates the vast gap between its market valuation, based on hopes for its future drug, and its minimal tangible assets, which is typical for the industry.
Debts of the company, segment and market as a whole
GLYC - Company debts GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotech focused on treating diseases in which carbohydrates play a key role. This chart reflects its financial position following the failure of key trials. The company is managing its remaining capital to advance its earlier research programs.
Market segment debts - Oncology targeted therapy
GlycoMimetics is a clinical-stage biotech company developing drugs to treat carbohydrate-related diseases. This is a complex and niche area of biochemistry. This chart clearly demonstrates the high financial risk and significant capital requirements for clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GlycoMimetics Inc.
GlycoMimetics is a clinical-stage oncology company. This chart shows its financial structure. For a biotech company whose future depends on the success of clinical trials, debt is a huge risk. A failure in research could make it impossible to finance.
Market segment debt to market segment book capitalization - Oncology targeted therapy
GlycoMimetics is a clinical-stage biopharmaceutical company developing drugs for the treatment of cancer and inflammatory diseases. This chart shows the debt burden in the biotech sector, a key indicator of a company's ability to fund its expensive research and development.
Debt to book value of all companies in the market
GlycoMimetics is a clinical-stage biotech company specializing in drugs that target carbohydrate molecules for the treatment of cancer and inflammatory diseases. This graph of total market debt serves as an indicator of investor risk appetite, which directly impacts the company's ability to fund its unique scientific approaches.
P/E of the company, segment and market as a whole
P/E - GlycoMimetics Inc.
GlycoMimetics is a biotech company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. This chart reflects the high risks associated with this innovative but complex scientific platform. Its performance is entirely dependent on clinical trial results.
P/E of the market segment - Oncology targeted therapy
GlycoMimetics is a clinical-stage biotech company developing drugs that target carbohydrate molecules (glycans) involved in cancer and inflammatory diseases. This chart shows the average valuation for the oncology sector, reflecting how investors evaluate innovative scientific approaches to treating diseases.
P/E of the market as a whole
GlycoMimetics is a biotech company developing drugs to treat cancer and inflammatory diseases. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GlycoMimetics Inc.
GlycoMimetics is a biotech company developing carbohydrate-mimicking drugs for the treatment of cancer and inflammatory diseases. This chart reflects market expectations for the success of its unique scientific approach. Future profits depend on clinical trial results and partnerships with major pharmaceutical companies.
%20P%2FE%20GlycoMimetics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GlycoMimetics-Inc.&v=1772476011051 "Chart of the company's future (projected) P/E GlycoMimetics Inc.")
Future (projected) P/E of the market segment - Oncology targeted therapy
GlycoMimetics is a clinical-stage biopharmaceutical company developing carbohydrate-mimicking drugs for the treatment of cancer and inflammatory diseases. The chart reflects average expectations for the oncology segment. GLYC's position relative to this benchmark reflects investor assessment of its unique scientific approach and progress in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772476011055 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
GlycoMimetics is a clinical-stage biopharmaceutical company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. This unique scientific approach is key to this. This chart of overall market expectations illustrates investor appetite for funding innovative but high-risk biotech platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772476011057 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotechnology company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. Its financial schedule is driven by research expenses. Potential profitability depends entirely on the success of its innovative approach to treating diseases.
Profit of companies in the market segment - Oncology targeted therapy
GlycoMimetics is a biopharmaceutical company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. This innovative approach to medicine is at the forefront of research. This chart shows the overall profitability of the targeted oncotherapy sector, reflecting investment interest and scientific progress in the development of new classes of anti-cancer drugs.
Overall market profit
GlycoMimetics is a biotech company developing drugs targeting carbohydrate molecules for the treatment of cancer and inflammatory diseases. Its future depends on the results of clinical trials. The positive economic backdrop, visible in this chart, is critical to attracting the investment needed to advance its innovative drug candidates.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GlycoMimetics Inc.
GlycoMimetics is a biopharmaceutical company developing drugs targeting carbohydrate molecules for the treatment of cancer and inflammatory diseases. This chart reflects analysts' speculative expectations regarding the potential of this unique scientific approach, which depends on the success of clinical trials.
%20profit%20of%20the%20company%20GlycoMimetics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GlycoMimetics-Inc.&v=1772476011063 "Graph of future (projected) profit of the company GlycoMimetics Inc.")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
GlycoMimetics is a biotech company developing carbohydrate-mimicking drugs for the treatment of oncology and inflammatory diseases. Its unique approach targets complex targets. The future depends on the success of clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing GlycoMimetics' innovative yet risky science.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772476011065 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
GlycoMimetics is a biotechnology company developing drugs for the treatment of oncology and inflammatory diseases. Its value and future are determined solely by the results of clinical trials. The overall macroeconomic indicators presented in this chart are irrelevant to its performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772476011067 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on developing drugs for the treatment of cancer and inflammatory diseases. With minimal revenue, its market value, reflected here, is a valuation of its unique scientific approach. Its growth is entirely dependent on the results of clinical trials.
P/S market segment - Oncology targeted therapy
GlycoMimetics is a biopharmaceutical company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. Future revenue depends on the success of its developments. This oncology chart reflects investor expectations for GlycoMimetics' unique scientific approach.
P/S of the market as a whole
GlycoMimetics is a clinical-stage biotech company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. This market revenue valuation chart helps understand how investors view this unique scientific approach and its potential for drug discovery.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotech company developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. This chart shows how the market assesses the future commercial potential of its unique scientific approach, banking on the success of clinical trials.
%20P%2FS%20GlycoMimetics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GlycoMimetics-Inc.&v=1772476011070 "The graph of the company's future (projected) P/S GlycoMimetics Inc.")
Future (projected) P/S of the market segment - Oncology targeted therapy
GlycoMimetics is a clinical-stage biotech company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. The company's valuation is based on investors' faith in its unique scientific approach and the potential of its candidates, particularly in the treatment of blood diseases, a high-risk bet.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772476011071 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
GlycoMimetics is a biotech company developing drugs that mimic carbohydrates for the treatment of oncological and inflammatory diseases. This unique scientific approach is key. Given the overall revenue projections shown in the chart, GlycoMimetics represents a venture capital investment in the future of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772476011071 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotechnology company specializing in the development of drugs for the treatment of cancer and inflammatory diseases. The company currently has no commercial products and, therefore, no sales revenue. Any revenue in the chart is attributed to partnerships.
Sales of companies in the market segment - Oncology targeted therapy
GlycoMimetics (GLYC) is a biotechnology company developing drugs that target carbohydrate biology to treat cancer and inflammatory diseases. This metric reflects revenue in the oncology sector. GlycoMimetics' innovative approach enables the creation of drugs that prevent cancer cells from "hiding" from chemotherapy, increasing its effectiveness.
Overall market sales
GlycoMimetics is a biotech company developing drugs targeting carbohydrate molecules involved in the development of cancer and inflammatory diseases. Its success depends on the results of clinical trials. This overall economic activity affects the investment climate in the biotech sector, which affects the company's ability to fund its research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GlycoMimetics Inc.
GlycoMimetics is a biotech company developing carbohydrate-mimicking drugs for the treatment of cancer and inflammatory diseases. Its future revenue depends on the success of clinical trials of its lead candidate for the treatment of acute myeloid leukemia. This chart reflects analyst forecasts, which assess the likelihood of commercialization of this innovative therapy.
%20sales%20of%20the%20company%20GlycoMimetics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GlycoMimetics-Inc.&v=1772476011075 "Schedule of future (projected) sales of the company GlycoMimetics Inc.")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
GlycoMimetics is a clinical-stage biopharmaceutical company specializing in carbohydrate biology-targeted drugs for the treatment of cancer and inflammatory diseases. This graph shows the potential future revenue from their pipeline of candidates. This is an analyst's perspective on the commercial prospects of their scientific approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772476011076 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
GlycoMimetics is a biotech company developing drugs that target carbohydrate molecules to treat cancer and inflammatory diseases. This innovative scientific approach is key. This graph reflects the overall investment climate, but for GlycoMimetics, demonstrating the clinical efficacy of its unique technology in challenging areas is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772476011077 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GlycoMimetics Inc.
GlycoMimetics is a clinical-stage biotechnology company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. Its financial performance reflects its high R&D expenditures. The chart shows its current profitability as an investment in a unique scientific approach that could lead to the creation of new drugs.
Market segment marginality - Oncology targeted therapy
GlycoMimetics is a clinical-stage biopharmaceutical company focused on developing drugs that mimic the structure of carbohydrates for the treatment of cancer and inflammatory diseases. This chart reflects its operating expenses. Future profitability depends on the success of its unique scientific approach and clinical programs.
Market marginality as a whole
GlycoMimetics is a clinical-stage biotech company developing drugs for the treatment of cancer and inflammatory diseases. Its future depends on successful trials. This total return chart reflects the investment climate. A favorable economic environment, with companies generally profitable, facilitates raising capital for risky biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company GlycoMimetics Inc.
GlycoMimetics is a biotech company using a unique approach to drug development, targeting carbohydrate molecules (glycans) that play a key role in cancer and inflammation. This graphic shows the team of scientists advancing this innovative approach through the complex stages of clinical trials.
Share of the company's employees GlycoMimetics Inc. within the market segment - Oncology targeted therapy
GlycoMimetics is a clinical-stage biotechnology company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. Its staff consists of highly specialized scientists. This chart shows the amount of intellectual capital the company is investing in this unique and complex field of science to create new drugs.
Number of employees in the market segment - Oncology targeted therapy
GlycoMimetics is a biotech company developing drugs that target carbohydrate biology to treat cancer and inflammatory diseases. This chart, showing employment in targeted oncology, illustrates the search for new drug targets. For GlycoMimetics, with its unique approach, growth in this field signifies recognition of the importance of glycobiology.
Number of employees in the market as a whole
GlycoMimetics is a biotech company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. Funding such cutting-edge research requires a favorable investment climate. The growth in overall employment, reflected in this chart, is a sign of a healthy economy where investors are willing to support long-term scientific projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GlycoMimetics Inc. (GLYC)
GlycoMimetics (GLYC) is a biotech company developing drugs (including oncology drugs) that target carbohydrate molecules. This is a highly specialized R&D company. This chart shows that the company's entire market value is derived from its unique scientific platform and pipeline. The value per employee is high because it is not tied to physical production.
%20of%20the%20company%20GlycoMimetics%20Inc.%20(GLYC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GlycoMimetics-Inc.-GLYC&v=1772476011082 "Chart of market capitalization per employee (in thousands of dollars) of the company GlycoMimetics Inc. (GLYC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
GlycoMimetics is a biotech company using a unique approach to drug discovery based on carbohydrate chemistry. Its market capitalization reflects the potential of this scientific platform. This chart shows the market premium placed on the company's innovations based on its focused scientific team.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772476011082 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
GlycoMimetics is a clinical-stage biotech company developing drugs to treat cancer and inflammatory diseases. Its value depends almost entirely on the success of clinical trials. This chart for GlycoMimetics is a prime example of a biotech company where the market value per employee can be colossal, reflecting the hope of developing a new drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772476011083 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GlycoMimetics Inc. (GLYC)
GlycoMimetics is a clinical-stage biotech company focused on oncology. The company is unprofitable. This graph will show a negative value—the loss per employee. This reflects the amount of capital the company is burning through on clinical research in the hopes of developing a new drug.
%20Chart%20GlycoMimetics%20Inc.%20(GLYC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GlycoMimetics-Inc.-GLYC&v=1772476011083 "Company Profit Per Employee (in thousands of dollars) Chart GlycoMimetics Inc. (GLYC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
GlycoMimetics is a biotech company developing drugs to treat diseases in which carbohydrates play a key role, including cancer. The scientific team's productivity in this complex field determines the company's future. This metric demonstrates the value each employee creates, which is an indicator of the effectiveness of its research platform.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772476011084 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
GlycoMimetics is a biotech company developing drugs that mimic the action of carbohydrates to treat cancer (especially blood cancer) and inflammatory diseases. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772476011085 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GlycoMimetics Inc. (GLYC)
GlycoMimetics is a clinical-stage biotech company developing drugs for the treatment of cancer and inflammatory diseases. Because it has no commercial products yet, revenue per employee is minimal or nonexistent. This chart clearly illustrates the R&D phase, where all value is generated through research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GlycoMimetics-Inc.-GLYC&v=1772476011085 "Sales chart per company employee GlycoMimetics Inc. (GLYC)")
Sales per employee in the market segment - Oncology targeted therapy
GlycoMimetics (GLYC) is a biotech company specializing in the development of drugs (glycomimetics) for the treatment of cancer and inflammatory diseases. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and personnel structure compared to other oncology biotechs.
Sales per employee for the market as a whole
GlycoMimetics (GLYC) is a clinical-stage biotech company focused on developing drugs that block specific carbohydrate bonds that play a role in the development of cancer and inflammation. The company has no commercial revenue. This near-zero figure reflects ongoing investment in its team of scientists conducting R&D in this complex field.
Short shares by company, segment and market as a whole
Shares shorted by company GlycoMimetics Inc. (GLYC)
GlycoMimetics (GLYC) is a clinical-stage biotech that recently suffered a devastating failure in a pivotal trial of its sickle cell disease drug. This chart shows short interest. The high bearish bets reflect investors' bets that the company has no valuable assets left in its pipeline and is headed for a devaluation. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GlycoMimetics-Inc.-GLYC&v=1772476011087 "Short Shares Chart for the Company GlycoMimetics Inc. (GLYC)")
Shares shorted by market segment - Oncology targeted therapy
GlycoMimetics (GLYC) is a biotech company developing drugs targeting carbohydrate biology for the treatment of cancer and inflammatory diseases. The chart below represents a general short position in the biotech sector, demonstrating investor skepticism regarding the success of risky clinical trials.
Shares shorted by the overall market
GlycoMimetics is a clinical-stage biotech. When this chart shows rising fear, speculative, pre-profit companies are the first to suffer. Investors aren't willing to wait years for FDA approval. They see GLYC as a money-burner and are selling off shares, fearing that in a risk-off environment, the company won't be able to attract new capital for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GlycoMimetics Inc. (GLYC)
GlycoMimetics is a biotech company developing drugs that mimic complex carbohydrates to treat cancer and inflammation. This is risky R&D. This graph is the "cardiogram" of clinical trials. It "overheats" to the extreme in anticipation of data and "cools" (falls) in the face of failure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GlycoMimetics-Inc.-GLYC&v=1772476011089 "RSI 14 indicator chart for the company's stock GlycoMimetics Inc. (GLYC)")
RSI 14 Market Segment - Oncology targeted therapy
GlycoMimetics is a biopharmaceutical company developing drugs that mimic the structure of carbohydrates (sugars) to treat cancer and inflammatory diseases. This approach is unique in oncology. This chart shows the overall "temperature" in the volatile targeted oncotherapy sector. It helps separate investor reactions to GLYC's clinical data from the general "hype" that has engulfed this niche.
RSI 14 for the overall market
GlycoMimetics (GLYC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GLYC (GlycoMimetics Inc.)
GlycoMimetics is a biotech company using glycobiology to develop drugs for cancer, specifically acute myeloid leukemia (AML). This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the clinical success of the company's key R&D candidate.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GLYC-GlycoMimetics-Inc.&v=1772476011092 "A chart showing analyst consensus forecasts for the expected stock price. GLYC (GlycoMimetics Inc.)")
The difference between the consensus estimate and the actual stock price GLYC (GlycoMimetics Inc.)
GlycoMimetics is a biotech company developing drugs (selectin inhibitors) for the treatment of blood cancer and sickle cell anemia. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their binary bet on the success of key clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GLYC-GlycoMimetics-Inc.&v=1772476011093 "A chart showing the difference between the consensus forecast and the actual stock price. GLYC (GlycoMimetics Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
GlycoMimetics is a biotech company developing drugs that "trick" cancer cells, blocking their ability to "hide" from chemotherapy. This chart shows general expectations for the targeted oncology sector. It reflects whether experts believe in the success of "combination" R&D approaches to cancer treatment.
Analysts' consensus forecast for the overall market share price
GlycoMimetics is a biotech company developing carbohydrate-based drugs for the treatment of blood cancers and inflammatory diseases. This chart reflects the overall market "risk appetite." For GlycoMimetics, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GlycoMimetics Inc.
GlycoMimetics is a biotech R&D company focused on glycobiology (sugars). Their R&D pipeline targets carbohydrate traps that cancer (especially blood cancer) uses to evade chemotherapy. This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Oncology targeted therapy
GlycoMimetics is an oncology biotech. They develop targeted drugs that trick cancer cells, making them vulnerable to chemotherapy. It's smart oncology. This chart compares their composite index to the sector, showing how their targeted approach outperforms the competition.
The AKIM Index for the overall market
GlycoMimetics is a biotech company developing glycomimetic drugs for the treatment of cancer (uproleselan) and inflammation. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, plagued by trial setbacks, compares to overall economic trends.
